Study of Resilience PRO Digital Symptom Monitoring to Improve Quality of Life in Adults With Cancer Receiving Systemic Treatment

What this Trial Is About

This clinical trial investigates whether Resilience PRO, a digital tool for remote symptom monitoring, can improve the quality of life for adults diagnosed with cancer who are receiving systemic anticancer treatment. The study compares patients using Resilience PRO plus their usual care to those receiving usual care alone. Resilience PRO is approved by French health authorities and designed to collect patient-reported outcomes electronically. Participants in the intervention group will use the Resilience PRO mobile app, which regularly asks about symptoms and sends alerts to the care team when important symptoms are reported. This allows timely adjustment of care. Both the intervention and control groups will continue to receive their usual cancer treatment and care. The trial is randomized and open-label. Throughout the study, researchers will measure quality of life after 3 months as the primary outcome. They will also evaluate health economics over 12 months and overall survival over 36 months. Participants will be monitored remotely using the app, and the study will assess how symptom monitoring affects their care and well-being over time.

Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only